623 related articles for article (PubMed ID: 20149736)
1. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
Thomas D; Henshaw R; Skubitz K; Chawla S; Staddon A; Blay JY; Roudier M; Smith J; Ye Z; Sohn W; Dansey R; Jun S
Lancet Oncol; 2010 Mar; 11(3):275-80. PubMed ID: 20149736
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I
Lancet Oncol; 2013 Aug; 14(9):901-8. PubMed ID: 23867211
[TBL] [Abstract][Full Text] [Related]
3. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
4. RANKL, denosumab, and giant cell tumor of bone.
Thomas DM
Curr Opin Oncol; 2012 Jul; 24(4):397-403. PubMed ID: 22581354
[TBL] [Abstract][Full Text] [Related]
5. Giant cell tumour of bone.
Thomas DM; Skubitz KM
Curr Opin Oncol; 2009 Jul; 21(4):338-44. PubMed ID: 19444102
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of denosumab in giant-cell tumour of bone.
Kyrgidis A; Toulis K
Lancet Oncol; 2010 Jun; 11(6):513-4. PubMed ID: 20522379
[No Abstract] [Full Text] [Related]
7. Denosumab: a breakthrough in treatment of giant-cell tumour of bone?
Balke M; Hardes J
Lancet Oncol; 2010 Mar; 11(3):218-9. PubMed ID: 20149737
[No Abstract] [Full Text] [Related]
8. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
[TBL] [Abstract][Full Text] [Related]
9. Denosumab: a new treatment option for giant cell tumor of bone.
Lewin J; Thomas D
Drugs Today (Barc); 2013 Nov; 49(11):693-700. PubMed ID: 24308016
[TBL] [Abstract][Full Text] [Related]
10. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma.
Vij R; Horvath N; Spencer A; Taylor K; Vadhan-Raj S; Vescio R; Smith J; Qian Y; Yeh H; Jun S
Am J Hematol; 2009 Oct; 84(10):650-6. PubMed ID: 19714603
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
12. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
13. Safety of denosumab in giant-cell tumour of bone.
Thomas D; Carriere P; Jacobs I
Lancet Oncol; 2010 Sep; 11(9):815. PubMed ID: 20816372
[No Abstract] [Full Text] [Related]
14. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.
Lau CP; Huang L; Wong KC; Kumta SM
Connect Tissue Res; 2013; 54(6):439-49. PubMed ID: 24060052
[TBL] [Abstract][Full Text] [Related]
15. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
Roitman PD; Jauk F; Farfalli GL; Albergo JI; Aponte-Tinao LA
Hum Pathol; 2017 May; 63():89-97. PubMed ID: 28235628
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases.
Deveci MA; Paydaş S; Gönlüşen G; Özkan C; Biçer ÖS; Tekin M
Acta Orthop Traumatol Turc; 2017 Jan; 51(1):1-6. PubMed ID: 27784623
[TBL] [Abstract][Full Text] [Related]
17. Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study.
Martin-Broto J; Cleeland CS; Glare PA; Engellau J; Skubitz KM; Blum RH; Ganjoo KN; Staddon A; Dominkus M; Feng A; Qian Y; Braun A; Jacobs I; Chung K; Atchison C
Acta Oncol; 2014 Sep; 53(9):1173-9. PubMed ID: 24834795
[TBL] [Abstract][Full Text] [Related]
18. Denosumab: Excellent response of metastatic giant cell tumor of the bone.
Ulas A; Bulent Akinci M; Silay K; Sendur MA; Sener Dede D; Yalcin B
J BUON; 2015; 20(2):666-7. PubMed ID: 26011370
[No Abstract] [Full Text] [Related]
19. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
[TBL] [Abstract][Full Text] [Related]
20. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
Cowan RW; Singh G; Ghert M
J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
